Cingulate Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 2.97 million compared to USD 4 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 7.08 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6611 USD | -4.59% |
|
-8.54% | -91.36% |
May. 21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
May. 08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-91.36% | 4.57M | |
+40.80% | 53.67B | |
+34.69% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- CING Stock
- News Cingulate Inc.
- Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024